Selexipag

What is Selexipag?

Selexipag is an oral medication primarily used for the long-term management of pulmonary arterial hypertension (PAH). It belongs to a class of drugs known as prostacyclin receptor agonists. Marketed under the brand name Uptravi, Selexipag works to improve exercise capacity and slow the progression of the disease in adults with PAH. It is not a cure for PAH but rather a crucial component in managing its challenging symptoms and improving patients' quality of life.

Pulmonary arterial hypertension is a rare, progressive disorder characterized by high blood pressure in the arteries leading from the heart to the lungs. This condition can lead to significant strain on the heart, resulting in symptoms like shortness of breath, fatigue, chest pain, and fainting. Selexipag offers a targeted approach to address the underlying vascular changes associated with PAH.

How Does Selexipag Work?

The mechanism of action of Selexipag is centered on its role as a selective agonist for the prostacyclin IP receptor. Prostacyclin is a naturally occurring substance in the body that helps relax blood vessels and prevent blood clots. In patients with pulmonary arterial hypertension (PAH), there is often a deficiency or impaired function of prostacyclin pathways.

Selexipag mimics the effects of natural prostacyclin by binding to and activating the IP receptor. This activation triggers a cascade of intracellular events, leading to increased levels of cyclic adenosine monophosphate (cAMP) within the smooth muscle cells of the pulmonary arteries. The increase in cAMP promotes vasodilation (the widening of blood vessels) and also inhibits the proliferation of smooth muscle cells and platelet aggregation. By promoting vasodilation, Selexipag reduces the resistance in the pulmonary arteries, thereby lowering the blood pressure in these vessels and reducing the workload on the right side of the heart. This improved blood flow to the lungs helps alleviate symptoms and improve exercise capacity in PAH patients.

Medical Uses of Selexipag

The primary medical use of Selexipag is for the treatment of pulmonary arterial hypertension (PAH) in adults. It is specifically indicated for patients with WHO functional class II-III PAH to delay disease progression and reduce the risk of hospitalization due to PAH. Selexipag can be used as monotherapy or in combination with other PAH treatments, depending on the patient's individual needs and response to therapy.

The goal of PAH treatment with Selexipag is to improve exercise tolerance, enhance the overall quality of life, and improve long-term outcomes for patients. Clinical studies have demonstrated its effectiveness in achieving these objectives, making it an important option in the comprehensive management strategy for PAH. Physicians often consider Selexipag for patients who require more aggressive therapy or who have not responded adequately to initial treatments.

Selexipag Dosage

The dosage of Selexipag must be carefully individualized by a healthcare professional, as it requires a gradual titration process to ensure optimal efficacy and minimize side effects. It is available in tablet form and is typically taken orally twice daily, approximately 12 hours apart, with or without food.

Treatment usually begins with a low starting dose, such as 200 micrograms (mcg) twice daily. The dose is then gradually increased, typically in increments of 200 mcg twice daily, at weekly intervals, based on the patient's tolerability. The goal is to reach the highest tolerated dose, up to a maximum of 1600 mcg twice daily. It is crucial for patients to adhere strictly to their prescribed dosing schedule and not to suddenly stop taking Selexipag, as abrupt discontinuation can lead to a worsening of PAH symptoms. Any missed doses or concerns about dosage should be discussed immediately with a doctor.

Selexipag Side Effects

Like all medications, Selexipag can cause side effects, although not everyone experiences them. Many of the common side effects are related to its vasodilatory action. These often include:

• Headache
• Jaw pain
• Nausea and vomiting
• Diarrhea
• Flushing (redness and warmth of the skin)
• Myalgia (muscle pain)
• Arthralgia (joint pain)
• Pain in extremities
• Hypotension (low blood pressure)

These side effects are generally mild to moderate and often lessen over time as the body adjusts to the medication. However, if they are severe or persistent, patients should inform their healthcare provider. More serious, though less common, side effects can include anemia, bleeding, or fluid retention. Patients should seek immediate medical attention if they experience severe chest pain, fainting, unusual bleeding or bruising, or signs of an allergic reaction.

Selexipag Drug Interactions

Selexipag can interact with other medications, potentially altering its effects or increasing the risk of side effects. It is primarily metabolized by the enzyme CYP2C8. Therefore, strong inhibitors of CYP2C8, such as gemfibrozil (used to lower cholesterol), can significantly increase the plasma concentration of Selexipag's active metabolite, potentially leading to an increased incidence and severity of adverse effects. Concomitant use with strong CYP2C8 inhibitors is generally not recommended.

Conversely, strong inducers of CYP2C8 may decrease Selexipag levels, potentially reducing its efficacy. Patients should also exercise caution when taking other vasodilators or antiplatelet agents concurrently with Selexipag, as this could exacerbate hypotension or increase the risk of bleeding, respectively. It is vital for patients to inform their doctor and pharmacist about all prescription, over-the-counter, and herbal supplements they are currently taking to avoid potentially harmful drug interactions.

Selexipag FAQ

Is Selexipag a cure for PAH?

No, Selexipag is not a cure for pulmonary arterial hypertension. It is a long-term treatment designed to manage the symptoms, improve exercise capacity, and delay the progression of the disease.

How long does it take for Selexipag to work?

The benefits of Selexipag are typically seen gradually over several weeks to months as the dose is slowly titrated upwards. Patients should not expect immediate relief of symptoms but rather a progressive improvement in their condition.

Can I stop taking Selexipag suddenly?

No, it is very important not to stop taking Selexipag suddenly without consulting your doctor. Abrupt discontinuation can lead to a rebound effect and a rapid worsening of PAH symptoms, which can be dangerous.

What is the brand name of Selexipag?

The brand name for Selexipag is Uptravi.

Can Selexipag be used during pregnancy?

Selexipag is generally not recommended during pregnancy unless the potential benefits outweigh the risks, as animal studies have shown adverse effects. Women of childbearing potential should use effective contraception during treatment.

Products containing Selexipag are available through trusted online pharmacies. You can browse Selexipag-based medications at ShipperVIP or Medicenter.

Summary of Selexipag

Selexipag stands as an important oral medication in the therapeutic arsenal against pulmonary arterial hypertension (PAH). As a selective prostacyclin receptor agonist, it works by promoting vasodilation in the pulmonary arteries, thereby reducing pulmonary pressure and improving blood flow to the lungs. This mechanism helps to alleviate the debilitating symptoms of PAH, improve exercise capacity, and delay disease progression. While requiring careful dose titration and monitoring for side effects, Selexipag, known by its brand name Uptravi, offers a valuable option for adults living with this chronic and challenging condition, ultimately aiming to enhance their quality of life and long-term prognosis.